Meritain Eldorado policies, page 8

Search Meritain Eldorado's public medical, payment and drug policies by CPT or HCPCS code, keyword or policy number, with links to the payer's own documents. Links open the payer's own document; check its current version before relying on it.

5,481 public policies Substrate tracks for Meritain Eldorado, by title.

Meritain Eldorado policies
PolicyDetailsCodesSource
0948-Emapalumab-lzsg (Gamifant)0948 · Commercial18Original policy ↗
0949-Caplacizumab-yhdp (Cablivi)0949 · Commercial10Original policy ↗
0950-Esketamine (Spravato)0950 · Commercial4Original policy ↗
0951-Brexanolone (Zulresso)0951 · Commercial3Original policy ↗
0952-Ultrasound Guidance - Selected Indications0952 · Commercial180Original policy ↗
0953-Onasemnogene Abeparvovec (Zolgensma and Itvisma)0953 · Commercial62Original policy ↗
0954-Romosozumab-aqqg (Evenity)0954 · Commercial8Original policy ↗
0955-Polatuzumab vedotin-piiq (Polivy)0955 · Commercial34Original policy ↗
0956-Docetaxel0956 · Commercial9Original policy ↗
0957-Calaspargase Pegol-mknl (Asparlas)0957 · Commercial2Original policy ↗
0958-Gemcitabine0958 · Commercial14Original policy ↗
0959-Pegaspargase (Oncaspar)0959 · Commercial5Original policy ↗
0960-Azacitidine0960 · Commercial4Original policy ↗
0961-Givosiran (Givlaari)0961 · Commercial4Original policy ↗
0962-Afamelanotide (Scenesse)0962 · Commercial1Original policy ↗
0963-Luspatercept-aamt (Reblozyl)0963 · Commercial5Original policy ↗
0964-Crizanlizumab-tmca (Adakveo)0964 · Commercial2Original policy ↗
0965-Drug Testing in Pain Management and Substance Use Disorder Treatment0965 · Commercial65Original policy ↗
0966-Fam-trastuzumab Deruxtecan-nxki (Enhertu)0966 · Commercial17Original policy ↗
0968-Peanut Immunotherapy0968 · Commercial5Original policy ↗
0969-Isatuximab-irfc (Sarclisa)0969 · Commercial14Original policy ↗
0970-Eptinezumab-jjmr (Vyepti)0970 · Commercial4Original policy ↗
0971-Sacituzumab govitecan-hziy (Trodelvy)0971 · Commercial19Original policy ↗
0972-Mitomycin Pyelocalyceal Solution (Jelmyto)0972 · Commercial4Original policy ↗
0973-Pertuzumab Products0973 · Commercial13Original policy ↗
0974-Ado-trastuzumab emtansine (Kadcyla)0974 · Commercial9Original policy ↗
0975-Inebilizumab-cdon (Uplizna)0975 · Commercial50Original policy ↗
0976-Plasminogen, Human-tvmh (Ryplazim)0976 · Commercial3Original policy ↗
0977-Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (Phesgo)0977 · Commercial2Original policy ↗
0978-Lurbinectedin (Zepzelca)0978 · Commercial53Original policy ↗
0979-Tafasitamab-cxix (Monjuvi)0979 · Commercial6Original policy ↗
0981-Belantamab Mafodotin-blmf (Blenrep)0981 · Commercial13Original policy ↗
0982-Remdesivir (Veklury)0982 · Commercial7Original policy ↗
0983-Lumasiran (Oxlumo)0983 · Commercial6Original policy ↗
0984-Naxitamab-gqgk (Danyelza)0984 · Commercial4Original policy ↗
0985-Margetuximab-cmkb (Margenza)0985 · Commercial5Original policy ↗
0986-Lisocabtagene Maraleucel (Breyanzi)0986 · Commercial7Original policy ↗
0987-Cabotegravir and Rilpivirine (Cabenuva)0987 · Commercial4Original policy ↗
0988-Trilaciclib (Cosela)0988 · Commercial2Original policy ↗
0989-Evinacumab-dgnb (Evkeeza)0989 · Commercial10Original policy ↗
0991-Fosdenopterin (Nulibry)0991 · Commercial5Original policy ↗
0992-Idecabtagene Vicleucel (Abecma)0992 · Commercial7Original policy ↗
0993-Dostarlimab-gxly (Jemperli)0993 · Commercial31Original policy ↗
0994-Loncastuximab Tesirine-lpyl (Zynlonta)0994 · Commercial6Original policy ↗
0995-Amivantamab-vmjw (Rybrevant) and Amivantamab and Hyaluronidase-lpuj (Rybrevant Faspro)0995 · Commercial15Original policy ↗
0996-Aducanumab-avwa (Aduhelm)0996 · Commercial20Original policy ↗
0997-Anifrolumab-fnia (Saphnelo)0997 · Commercial38Original policy ↗
0998-Tisotumab Vedotin-tftv (Tivdak)0998 · Commercial5Original policy ↗
0999-Prescription Digital Therapeutics0999 · Commercial10Original policy ↗
1000-Triamcinolone Acetonide Injectable Suspension (Xipere)1000 · Commercial2Original policy ↗

Back to Meritain Eldorado

Disclaimer

The information provided on this page is for general informational purposes only and does not constitute billing, coding, or reimbursement advice. Nothing on this page should be relied upon as a substitute for clinician assessment, professional billing guidance, or as a definitive statement of any payor's billing requirements or policies.

Payor agreements, fee schedules, and billing policies vary and are subject to change. Before submitting any claims related to maternity care services, including claims affected by the 2027 CPT code revisions, please consult the applicable payor agreements, coverage policies, and billing guidelines to confirm current requirements for their specific payor contracts.

Substrate makes no representation or warranty regarding the accuracy, completeness, or timeliness of the payor-specific information presented here. Providers are solely responsible for ensuring that all claims are submitted in accordance with applicable payor requirements, and Substrate assumes no liability for claim denials, underpayments, or other adverse outcomes arising from reliance on this information.